Reducing the amyloid burden through immunotherapy: A major therapeutic advance

Nephrology Dialysis Transplantation

Volumn 26, Issue 5, 2011, Pages 1471-1473

  Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; SERUM AMYLOID A;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; DRUG TARGETING; FEASIBILITY STUDY; HEART FUNCTION; HUMAN; IMMUNOTHERAPY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; NONHUMAN; ORGAN INJURY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; TRANSLATIONAL RESEARCH;

AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY;

EID: 79955593956     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr101     Document Type: Article

References (20)

1. Bodin K, Ellmerich S, Kahan MC et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93-97
2. Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmacologic-al depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254-259 (Pubitemid 34534701)
3. Gillmore JD, Tennent GA, Hutchinson WL et al. Sustained pharma-cological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010; 148: 760-767
4. Sipe JD, Benson MD, Buxbaum JN et al. Amyloid fibril protein no-menclature: 2010 recommendations from the nomenclature commit-tee of the International Society of Amyloidosis. Amyloid 2010; 17: 101-104
5. Merlini G Bellotti V Molecular mechanisms of amyloidosis. N Engl JMed 2003; 349: 583-596 (Pubitemid 36951371)
6. Obici L Perfetti V Palladini G et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11-22 (Pubitemid 41597427)
7. Dember LM. Amyloidosis-associated kidney disease. JAm Soc Ne-phrol 2006; 17: 3458-3471 (Pubitemid 44865288)
8. Obici L, Raimondi S, Lavatelli F et al. Susceptibility to AA amyloid-osis in rheumatic diseases: A critical overview. Arthritis Rheum 2009; 61: 1435-1440
9. Pettersson T, Konttinen YT, Maury CP. Treatment strategies for amyl-oid A amyloidosis. Expert Opin Pharmacother 2008; 9: 2117-2128
10. Dember LM, Hawkins PN, Hazenberg BP et al. Eprodisate for the treatment ofrenal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-2360 (Pubitemid 46883769)
11. Fu HJ, Liu B, Frost JL et al. Amyloid-beta immunotherapy for Alz-heimer's disease. CNS Neurol Disord Drug Targets 2010; 9: 197-206
12. Wall JS, Kennel SJ, Stuckey AC et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010; 116: 2241-2244
13. Verschueren P, Lensen F, Lerut E et al. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflam-matory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003; 62: 368-369 (Pubitemid 36363449)
14. Simsek I, Kaya A, Erdem H et al. No regression of renal amyl-oid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy J Nephrol 2010; 23: 119-123
15. Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371 (Pubitemid 46883770)
16. Palladini G, Campana C, Klersy C et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445 (Pubitemid 36605226)
17. Palladini G, Lavatelli F, Russo P et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-3858 (Pubitemid 43726787)
18. Palladini G, Barassi A, Klersy C et al. The combination of high-sen-sitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemother-apy best predicts survival in AL amyloidosis. Blood 2010; 116: 3426-3430
19. Bellotti V, Nuvolone M, Giorgetti S et al. The workings of the amyl-oid diseases. Ann Med 2007; 39: 200-207
20. Kumar SK, Gertz MA, Lacy MQ et al. Recent improvements in sur-vival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86: 12-18